As of November 10, 2026, Zentalis Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ZNTL); its largest reported holder is Walters William T, with 18.8% on Schedule 13G/A of August 19, 2026, then Andrew J. Schwab (6.4%). The largest insider holding is Walters Group, a 10% owner, with 17,844,973 shares (18.2% of shares outstanding), per Form 4 of August 19, 2026 (Schedule 13G/A, August 19, 2026).
Is this your company?
About to sign with, pay or invest in Zentalis Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Zentalis Pharmaceuticals, Inc. a real, registered company?
- Zentalis Pharmaceuticals, Inc. files with the SEC under CIK 1725160 (its SEC filings).
- Its shares are listed under the ticker ZNTL on Nasdaq (SEC company record).
- business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ZENTALIS PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-10).
- Leadership changes: the latest reported is Shannon Campbell, Director (Form 8-K filed 2026-05-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Walters William T (filed 2026-08-19).
Who are Zentalis Pharmaceuticals, Inc.'s owners and officers?
Zentalis Pharmaceuticals, Inc.: business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 4.1% |
| Schedule 13G/A, 2026-08-19 | Walters William T | 18.8% |
| Schedule 13G/A, 2026-08-13 | Barclays PLC | 3.17% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 5.2% |
| Schedule 13G, 2026-03-03 | Squadron Master Fund LP | 5.1% |
| Schedule 13G/A, 2026-01-05 | Walters William T | 19.7% |
| Schedule 13D/A, 2026-01-02 | Matrix Capital Management Company, LP | 0% |
| Schedule 13G, 2025-12-30 | Andrew J. Schwab | 6.4% |
| Schedule 13D/A, 2025-12-15 | Matrix Capital Management Company, LP | 9.98% |
| Schedule 13G, 2025-11-12 | Barclays PLC | 5.32% |
| Schedule 13G/A, 2025-10-14 | Millennium Management LLC | 1.3% |
| Schedule 13G/A, 2025-07-16 | Blackrock, Inc. | 2.2% |
Questions about who owns Zentalis Pharmaceuticals, Inc.
Who owns Zentalis Pharmaceuticals, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Zentalis Pharmaceuticals, Inc.: Walters William T (18.8%, Schedule 13G/A, filed 2026-08-19), Andrew J. Schwab (6.4%, Schedule 13G, filed 2025-12-30) and Squadron Master Fund LP (5.1%, Schedule 13G, filed 2026-03-03).
Who are the largest shareholders of Zentalis Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Zentalis Pharmaceuticals, Inc. on this page are Walters William T (18.8%), Andrew J. Schwab (6.4%) and Squadron Master Fund LP (5.1%).
When did Walters William T buy into Zentalis Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Walters William T on this page is the Schedule 13G/A, filed 2026-01-05, reporting 19.7%; its latest, Schedule 13G/A filed 2026-08-19, reports 18.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Zentalis Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zentalis Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zentalis Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-27 | Shannon Campbell | Director | appointed | 2026-05-22 |
Which insiders own Zentalis Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Walters Group, a 10% owner: 17,844,973 shares (18.2% of shares outstanding), on a joint filing (Form 4, 2026-08-19).
- , a 10% owner: 17,844,973 shares (18.2% of shares outstanding), on a joint filing (Form 4, 2026-08-19).
- , a 10% owner: 17,844,973 shares (18.2% of shares outstanding), on a joint filing (Form 4, 2026-08-19).
- , a 10% owner: 6,459,973 shares (6.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-15).
- Matrix Capital Management Company, LP, a 10% owner: 6,459,973 shares (6.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-15).
Shares outstanding: 98,265,863 as of 2026-11-04, from the company's latest SEC cover page.
How much has Zentalis Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Zentalis Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Zentalis Pharmaceuticals, Inc. and the records around it.
Zentalis Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes May 2026
Companies that share a holder
- Matrix Capital Management Company, LP also filed stake reports on 2 other companies: Aura Biosciences, Inc. (May 2026), Maze Therapeutics, Inc. (Nov 2025)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/zentalis-pharmaceuticals